PharmiWeb10d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...
pharmaphorum10d
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Hosted on MSN28d
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial
The ongoing study is an open-label, multicenter trial designed ... the potential to change the treatment landscape for DME, diabetic retinopathy, and wet age-related macular degeneration ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Pharmabiz4d
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...
Onlymyhealth28d
Is Ozempic Truly A ‘Miracle Drug’ For Weight Loss? Understanding The Safety And Effectiveness Concerns
With rumours about celebrities using semaglutide drugs like Ozempic for quick weight loss the question remains Are these anti-diabetic medications truly the ‘miracle drugs’ theyre claimed to be We ask ...
Retina Labs Direct-To-Patient At-Home Lab Testing Programs Help Health Plans Boost Star Ratings
In-Home Preventive Care Screening Programs Close Critical HEDIS Gaps in Care Measures & Improve Compliance Rates Through Multi-Cha ...
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
ophthalmologytimes29d
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
The phase 1 trial is a multicenter, open-label, dose-escalation study assessing OCU200's safety via intravitreal injections in three dosage cohorts. Ocugen aims for OCU200 to be a first-line therapy ...